Gene Variants in Angiogenesis and Lymphangiogenesis and Cutaneous Melanoma Progression

Background: Angiogenesis and lymphangiogenesis are important in the progression of melanoma. We investigated associations between genetic variants in these pathways with sentinel lymph node (SLN) metastasis and mortality in 2 independent series of patients with melanoma. Methods: Participants at Moffitt Cancer Center were 552 patients, all Caucasian, with primary cutaneous melanoma referred for SLN biopsy. A total of 177 patients had SLN metastasis, among whom 60 died from melanoma. Associations between 238 single-nucleotide polymorphisms (SNP) in 26 genes and SLN metastasis were estimated as ORs and 95% confidence intervals (CI) using logistic regression. Competing risk regression was used to estimate HRs and 95% CI for each SNP and melanoma-specific mortality. We attempted to replicate significant findings using data from a genome-wide association study comprising 1,115 patients with melanoma who were referred for SLN biopsy from MD Anderson Cancer Center (MDACC), among whom 189 patients had SLN metastasis and 92 patients died from melanoma. Results: In the Moffitt dataset, we observed significant associations in 18 SNPs with SLN metastasis and 17 SNPs with mortality. Multiple SNPs in COL18A1, EGF receptor (EGFR), FLT1, interleukin (IL)-10, platelet-derived growth factor D (PDGFD), PIK3CA, and toll-like receptor (TLR)-3 were associated with the risk of SLN metastasis and/or patient mortality. The MDACC data set replicated an association between mortality and rs2220377 in PDGFD. Furthermore, in a meta-analysis, 3 additional SNPs were significantly associated with SLN metastasis (EGFR rs723526 and TLR3 rs3775292) and melanoma-specific death (TLR3 rs7668666). Conclusions: These findings suggest that genetic variation in angiogenesis and lymphangiogenesis contributes to regional nodal metastasis and progression of melanoma. Impact: Additional research attempting to replicate these results is warranted. Cancer Epidemiol Biomarkers Prev; 22(5); 827–34. ©2013 AACR.

[1]  T. Sellers,et al.  Gene variants in the angiogenesis pathway and prostate cancer. , 2012, Carcinogenesis.

[2]  Victor G Prieto,et al.  Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression , 2012, Melanoma research.

[3]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[4]  Caitlin P. McHugh,et al.  Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. , 2011, Human molecular genetics.

[5]  Suephy C. Chen,et al.  Melanoma reporting to central cancer registries by US dermatologists: an analysis of the persistent knowledge and practice gap. , 2011, Journal of the American Academy of Dermatology.

[6]  W. Peitsch,et al.  Ultraviolet light tattoo complicated by granulomatous inflammation. , 2011, Journal of the American Academy of Dermatology.

[7]  D. Schadendorf,et al.  Association of Inherited Variation in Toll-Like Receptor Genes with Malignant Melanoma Susceptibility and Survival , 2011, PloS one.

[8]  Jo Lambert,et al.  EGFR in melanoma: clinical significance and potential therapeutic target , 2011, Journal of cutaneous pathology.

[9]  K. Alitalo,et al.  Perspectives on lymphangiogenesis and angiogenesis in cancer , 2011, Journal of surgical oncology.

[10]  Jeffrey E Gershenwald,et al.  Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Rigel.  Trends in dermatology: melanoma incidence. , 2010, Archives of dermatology.

[12]  Yurii S. Aulchenko,et al.  ProbABEL package for genome-wide association analysis of imputed data , 2010, BMC Bioinformatics.

[13]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Sleeman,et al.  Tumor metastasis and the lymphatic vasculature , 2009, International journal of cancer.

[15]  X. Sun,et al.  Clinical and biological significance of angiogenesis and lymphangiogenesis in colorectal cancer. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[16]  Yihai Cao.  Why and how do tumors stimulate lymphangiogenesis? , 2008, Lymphatic research and biology.

[17]  T. Niu,et al.  Missense Polymorphisms in Matrix Metalloproteinase Genes and Skin Cancer Risk , 2008, Cancer Epidemiology Biomarkers & Prevention.

[18]  D. Morton,et al.  Activation of toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors , 2008, Molecular Cancer Therapeutics.

[19]  L. Akslen,et al.  Mutation analysis of the EGFR–NRAS–BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma , 2008, Melanoma research.

[20]  Helen Y Wang,et al.  Toll-like receptors and immune regulation: implications for cancer therapy , 2008, Oncogene.

[21]  M. Detmar,et al.  Chapter 1. Inflammation, angiogenesis, and lymphangiogenesis. , 2008, Methods in enzymology.

[22]  Zhiwei Wang,et al.  Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of notch-1 and nuclear factor-κB signaling , 2007 .

[23]  A. Maminishkis,et al.  PDGF-C and -D induced proliferation/migration of human RPE is abolished by inflammatory cytokines. , 2007, Investigative ophthalmology & visual science.

[24]  M. Vuoristo.  The polymorphisms of interleukin-10 gene influence the prognosis of patients with advanced melanoma. , 2007, Cancer genetics and cytogenetics.

[25]  C. Sander,et al.  Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma , 2007, BMC Medical Genetics.

[26]  H. Pehamberger,et al.  The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. , 2006, The Journal of investigative dermatology.

[27]  Michael Detmar,et al.  Tumor and lymph node lymphangiogenesis—impact on cancer metastasis , 2006, Journal of leukocyte biology.

[28]  R. Elashoff,et al.  Sentinel-node biopsy or nodal observation in melanoma. , 2006, The New England journal of medicine.

[29]  D. Pinkel,et al.  PI3-kinase subunits are infrequent somatic targets in melanoma. , 2006, The Journal of investigative dermatology.

[30]  D. Mestel,et al.  FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients , 2006, British Journal of Cancer.

[31]  J. Hansson,et al.  Mutations of PIK3CA are rare in cutaneous melanoma , 2006, Melanoma research.

[32]  J. Malvehy,et al.  Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case–control study , 2006, Journal of Clinical Pathology.

[33]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, , 2006 .

[34]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[35]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[36]  A. Hauschild,et al.  Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes , 2005, Modern Pathology.

[37]  R. Elashoff,et al.  Sentinel Node Biopsy for Early-Stage Melanoma: Accuracy and Morbidity in MSLT-I, an International Multicenter Trial , 2005, Annals of surgery.

[38]  C. Gutiérrez,et al.  Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease , 2005, Melanoma research.

[39]  K. Alitalo,et al.  PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. , 2004, Blood.

[40]  T. Sjöblom,et al.  Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. , 2004, Cancer research.

[41]  D. Bates,et al.  Lymphatic density and metastatic spread in human malignant melanoma , 2004, British Journal of Cancer.

[42]  Toshihiro Tanaka.  The International HapMap Project , 2003, Nature.

[43]  S. Turner,et al.  Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma. , 2003, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[44]  Michael Detmar,et al.  Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. , 2003, The American journal of pathology.

[45]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[46]  S. Turner,et al.  Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma , 2002, Genes and Immunity.

[47]  M. Jeffers,et al.  Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer. , 2002, Cancer research.

[48]  Andrew G Smith,et al.  Association between functional polymorphism in EGF gene and malignant melanoma , 2002, The Lancet.

[49]  A. Bateman,et al.  IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma , 2001, Genes and Immunity.

[50]  M. Ross,et al.  Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  D. Ruiter,et al.  Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. , 1992, The Journal of investigative dermatology.

[52]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[53]  C. Balch,et al.  The prognostic significance of ulceration of cutaneous melanoma , 1980, Cancer.

[54]  A Breslow,et al.  Thickness, Cross‐Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma , 1970, Annals of surgery.